-61.4%
CLSK vs GSK
+97.8%
-159.2%
-98.6%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for all.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | +6.2% | -2.7% | +8.9% | +6.2% |
| 7D | +21.9% | -4.2% | +26.1% | +21.8% |
| 30D | +9.6% | -7.5% | +17.1% | +9.5% |
| 3M | -18.4% | -3.3% | -15.1% | -18.5% |
| 6M | +46.4% | -9.3% | +55.7% | +46.4% |
| YTD | +33.2% | +1.6% | +31.6% | +33.0% |
| 1Y | +47.0% | +25.5% | +21.5% | +45.6% |
| 3Y | +206.4% | +49.3% | +157.1% | +200.7% |
| 5Y | +5.4% | +46.7% | -41.3% | +2.3% |
| All | -61.4% | +97.8% | -159.2% | -42.1% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over all: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
all analysis · Full analysis span regression · 6 months rolling